Xynos Konstantinos 4
4 · Replimune Group, Inc. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Replimune (REPL) CMO Konstantinos Xynos Sells 14,023 Shares
What Happened Konstantinos Xynos, Chief Medical Officer of Replimune Group (REPL), reported the sale of 14,023 shares on 2026-05-18 for total proceeds of approximately $71,237. The filing lists a weighted average price of $5.08 per share, and the sale was reported under transaction code "S" (sale).
Key Details
- Transaction date: 2026-05-18; Form 4 filed: 2026-05-20 (appears timely for a Form 4 filing).
- Shares sold: 14,023; reported aggregate proceeds: $71,237.
- Price details: weighted average reported as $5.08; footnote says shares were sold in multiple transactions at prices ranging $5.01–$5.08.
- Footnote: Sale was a "sell to cover" to satisfy tax withholding on partial RSU vesting and was made under an irrevocable provision in the award agreement (not a discretionary sale).
- Shares owned after the transaction: Not disclosed in the information provided in this summary.
Context This was a tax-withholding sale tied to RSU vesting (routine, non-discretionary), not an open-market investment decision. Retail investors typically treat such sell-to-cover transactions as administrative and not a signal of the insider's view on the company's prospects.
Insider Transaction Report
Form 4
Xynos Konstantinos
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-05-18$5.08/sh−14,023$71,237→ 235,662 total
Footnotes (2)
- [F1]Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.
- [F2]The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $5.01 to $5.08 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.
Signature
/s/ Shawn Glidden, attorney-in-fact|2026-05-20